Validating the 2022 <scp>WHO</scp> classification in thyroid carcinomas: Prospective evidence for predicting iodine resistance

The 2022 WHO classification improves RAIR disease prediction, notably by recognizing high-grade carcinomas as a distinct entity. High-grade factors, especially tumour necrosis, which emerges as a key predictive factor, should be systematically reported in thyroid carcinoma pathology reports to enhance patient management and follow-up.